Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

Cesne, A. L., Judson, I., Maki, R., Grosso, F., Schuetze, S., Mehren, M. V., Chawla, S. P., Demetri, G. D., Nieto, A., Tanovic, A., Blay, J. Y. (October 2013) Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. Br J Cancer, 109 (7). pp. 1717-24. ISSN 1532-1827 (Electronic)0007-0920 (Linking)

URL: https://www.ncbi.nlm.nih.gov/pubmed/24022187
DOI: 10.1038/bjc.2013.524

Abstract

BACKGROUND: This retrospective pooled analysis assessed the effect of age on the efficacy and safety of trabectedin in young and elderly patients with recurrent advanced soft tissue sarcoma (STS). METHODS: Data from 350 adults with STS treated in five phase II trials with trabectedin were divided in the younger (<60 years; n=267) and the older cohort (>/=60 years; n=83). RESULTS: The response rate did not differ with age (younger: 10.1% vs elderly 9.6%). No significant differences were found in median progression-free survival (PFS) in younger (2.5 months) and older (3.7 months) cohort with a comparable PFS rates at 3 (45.1% vs 55.1%) and 6 months (29.5% vs 36.4%). Similar median overall survival was observed in both cohorts (13.0 vs 14.0 months). Reversible neutropenia and aspartate aminotransferase/alanine aminotransferase elevation were the most common abnormalities. A higher incidence of grade 3/4 neutropenia (43.6% vs 60.2%) and fatigue (6.3% vs 14.4%) was observed in older patients. In 24 patients aged >/=70 years, no significant differences in efficacy or safety outcomes were found. CONCLUSION: This analysis demonstrated that trabectedin is a feasible treatment in young and elderly patients with STS, with meaningful clinical benefits and an acceptable safety profile, essential in palliative treatment of elderly patients.

Item Type: Paper
Uncontrolled Keywords: Adult Age Factors Aged Aged, 80 and over Antineoplastic Agents, Alkylating/adverse effects/*therapeutic use Dioxoles/adverse effects/*therapeutic use Disease-Free Survival Female Humans Male Middle Aged Retrospective Studies Sarcoma/*drug therapy/*mortality Tetrahydroisoquinolines/adverse effects/*therapeutic use Treatment Outcome Young Adult
Subjects: diseases & disorders > cancer > drugs and therapies
diseases & disorders > cancer > cancer types > sarcoma
CSHL Authors:
Communities: CSHL labs > Maki lab
Depositing User: Matt Covey
Date: 1 October 2013
Date Deposited: 20 Oct 2016 15:57
Last Modified: 20 Oct 2016 15:57
PMCID: PMC3790176
Related URLs:
URI: http://repository.cshl.edu/id/eprint/33746

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving